Sarepta therapeutics shares new protein expression and safety results from endeavor in participants 2 years old at time of treatment

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today reported new results from study 9001-103. also known as endeavor, study 9001-103 is a multi-cohort study of elevidys (delandistrogene moxeparvovec-rokl) for the treatment of duchenne muscular dystrophy. treatment with elevidys in the endeavor participants in cohort 6 who were 2 years old at the time of treatment (n=6), demonstrated mean expression of 93.
SRPT Ratings Summary
SRPT Quant Ranking